Immune profiles according to EGFR mutant subtypes and correlation with PD-1/PD-L1 inhibitor therapies in lung adenocarcinoma
暂无分享,去创建一个
Bumhee Park | Y. Koh | J. Han | Hyun Woo Lee | J. Han | S. Haam | Se Hee Jung | Hyun Woo Lee
[1] Y. Shang,et al. PD-L1 expression, tumor mutational burden, and immune cell infiltration in non-small cell lung cancer patients with epithelial growth factor receptor mutations , 2022, Frontiers in Oncology.
[2] W. Zhong,et al. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma , 2022, Journal for ImmunoTherapy of Cancer.
[3] J. Roth,et al. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer , 2021, Journal for ImmunoTherapy of Cancer.
[4] Taicheng Zhou,et al. Molecular Subtypes and CD4+ Memory T Cell-Based Signature Associated With Clinical Outcomes in Gastric Cancer , 2021, Frontiers in Oncology.
[5] J. Christensen,et al. Cytotoxic CD8+ T cells in cancer and cancer immunotherapy , 2020, British Journal of Cancer.
[6] E. Richardson,et al. Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms , 2020, Cancer Gene Therapy.
[7] Sara R. Savage,et al. Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma , 2020, Cell.
[8] K. Horimoto,et al. CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy , 2019, Cancer Immunology Research.
[9] A. Drilon,et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] E. Tartour,et al. Distinct prognostic value of circulating anti-telomerase CD4+ Th1 immunity and exhausted PD-1+/TIM-3+ T cells in lung cancer , 2019, British Journal of Cancer.
[11] N. Schultz,et al. EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] J. Gu,et al. PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis. , 2019, Future oncology.
[13] Ash A. Alizadeh,et al. Determining cell-type abundance and expression from bulk tissues with digital cytometry , 2019, Nature Biotechnology.
[14] J. Galon,et al. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies , 2019, Nature Reviews Drug Discovery.
[15] J. Lunceford,et al. IFN-g – related mRNA profile predicts clinical response to PD-1 blockade , 2019 .
[16] K. Syrigos,et al. Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[17] J. Luke,et al. T Cell–Inflamed versus Non-T Cell–Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection , 2018, Cancer Immunology Research.
[18] X. Liu,et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response , 2018, Nature Medicine.
[19] J. Borst,et al. CD4+ T cell help in cancer immunology and immunotherapy , 2018, Nature Reviews Immunology.
[20] Caicun Zhou,et al. Lung cancer in never smokers-the East Asian experience. , 2018, Translational lung cancer research.
[21] Peter W. Laird,et al. Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer , 2018, Cell.
[22] B. O'Sullivan,et al. 106PThe association between PD-L1 expression, EGFR mutation and ALK translocation in a series of 982 lung cancers , 2017 .
[23] Yi-long Wu,et al. EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer , 2017, Oncoimmunology.
[24] J. Lunceford,et al. IFN-&ggr;–related mRNA profile predicts clinical response to PD-1 blockade , 2017, The Journal of clinical investigation.
[25] F. Hirsch,et al. PD‐L1 Expression in Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[26] S. Digumarthy,et al. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis , 2016, Clinical Cancer Research.
[27] L. Crinò,et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[28] Martin L. Miller,et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.
[29] T. Gajewski,et al. The STING pathway and the T cell-inflamed tumor microenvironment. , 2015, Trends in immunology.
[30] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[31] R. Kennedy,et al. Multiple roles for CD4+ T cells in anti‐tumor immune responses , 2008, Immunological reviews.
[32] F. Schmidt. Meta-Analysis , 2008 .
[33] E. Tartour,et al. Prognostic Value of Tumor-Infiltrating CD4+ T-Cell Subpopulations in Head and Neck Cancers , 2006, Clinical Cancer Research.
[34] M. F. Parry,et al. A Retrospective Analysis , 1990 .